AeproMED
AeproMED revolutionizes healthcare with personalized medicine through state-of-the-art aerosol technology and integrated bio-signal detection. The company focuses on developing innovative inhalation therapy platforms, including nebulizers and drug delivery systems, to improve treatment efficacy and patient outcomes. With a commitment to precision medicine, AeproMED collaborates with biotech, pharmaceutical, and ICT partners to advance inhalation therapies and digital health solutions.
Industries
Nr. of Employees
small (1-50)
AeproMED
7F.-5, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 302041, Taiwan
Patents
Products
Nebulizer devices for preclinical and clinical use
Nebulizer hardware engineered for animal models and human clinical trials, incorporating vibrating mesh aerosol generation and configurable delivery parameters for varied formulations.
Nebulizer devices for preclinical and clinical use
Nebulizer hardware engineered for animal models and human clinical trials, incorporating vibrating mesh aerosol generation and configurable delivery parameters for varied formulations.
Services
Integrated service combining adaptive aerosol delivery and breath‑synchronized monitoring to support personalized inhalation therapy and clinical trial collaborations with pharma and hospitals.
Laboratory services for aerosol feasibility testing, formulation‑device matching, atomization property analysis, and simulation of human lung drug deposition.
Engineering and development assistance for nebulizer devices including prototype development, performance testing, and preparation for clinical use.
Integrated service combining adaptive aerosol delivery and breath‑synchronized monitoring to support personalized inhalation therapy and clinical trial collaborations with pharma and hospitals.
Laboratory services for aerosol feasibility testing, formulation‑device matching, atomization property analysis, and simulation of human lung drug deposition.
Engineering and development assistance for nebulizer devices including prototype development, performance testing, and preparation for clinical use.
Expertise Areas
- Inhalation drug delivery
- Nebulizer device engineering
- Digital health and breath‑synchronized monitoring
- Aerosol characterization and lung deposition modelling
Key Technologies
- Adaptive frequency aerosol delivery
- Breath‑synchronized drug delivery systems
- Vibrating mesh nebulizer technology
- AI-driven atomization optimization
News & Updates
The CEO Vicky Chang received the third award at the AWE Accelerator Demo Day, highlighting the company's innovation and market competitiveness.
The company held a ribbon-cutting ceremony and opened a new chapter in precision inhalation therapy, collaborating with academic and government units.
The company shared insights on its technological advancements and future prospects in inhalation therapy.
An exploration of inhaled drug delivery as a promising approach for systemic treatment, including drug types and technological innovations.
AeproMED received this award in 2023 for its innovative inhalation platform that enhances drug stability and targeted delivery.
The CEO Vicky Chang received the third award at the AWE Accelerator Demo Day, highlighting the company's innovation and market competitiveness.
The company held a ribbon-cutting ceremony and opened a new chapter in precision inhalation therapy, collaborating with academic and government units.
The company shared insights on its technological advancements and future prospects in inhalation therapy.
An exploration of inhaled drug delivery as a promising approach for systemic treatment, including drug types and technological innovations.
AeproMED received this award in 2023 for its innovative inhalation platform that enhances drug stability and targeted delivery.